Actively Recruiting
Study of Xuesaitong Soft Capsules for Reducing Inflammation and Heart Risks in Adults With Coronary Heart Disease
Led by China National Center for Cardiovascular Diseases · Updated on 2025-09-08
240
Participants Needed
2
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effects of Xuesaitong Soft Capsules on patients with coronary heart disease in a multicenter, randomized, double-blind, placebo-controlled trial. The study involves 240 eligible patients aged 18 years or older and aims to assess changes in high-sensitivity C-reactive protein hsCRP levels over 12 weeks. This research also monitors other inflammation markers, platelet function, blood vessel health, blood lipids, angina symptoms, and quality of life scores, while evaluating safety. Participants will be randomly assigned to receive either Xuesaitong Soft Capsules at a daily dose of 1.32 grams or a matching placebo. The treatment period lasts for 3 months, during which the impact of the capsules on various clinical and laboratory indicators will be compared to placebo. The study uses a quadruple masking design to ensure unbiased results. During the trial, participants will undergo regular assessments including blood tests for inflammation and lipid profiles, functional tests for endothelial and platelet activity, and questionnaires to measure angina and health status. Researchers will track medication adherence and safety outcomes throughout the 12-week follow-up. The study uses statistical models to analyze changes in these measures from baseline to the end of the treatment period.
CONDITIONS
Brief Title
Effect of Xuesaitong Soft Capsules on Major Risk Factors in Patients With Coronary Heart Disease
Research Team
J
Jing Li, MD, PhD
Y
Yan Li, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here